Annovis Bio, Inc. (ANVS) Income Statement
ANVS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsANVS revenue and net income
ANVS profit margins
ANVS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ANVS quarterly EPS vs estimates
Annovis Bio beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.30).
ANVS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $185,175 |
| Cost of revenue | — | — | — | — | — | — | — | — | — | $11,452 |
| Gross profit | — | — | — | — | — | — | — | — | — | $173,723 |
| Research & development | $25.2M | $20.0M | $38.8M | $16.5M | $8.5M | $3.1M | $776,256 | $111,608 | $273,370 | — |
| Sales, general & admin | $4.5M | $6.8M | $6.3M | $9.0M | $6.1M | $3.6M | $829,366 | $602,329 | $409,063 | $1.9M |
| Total operating expenses | $29.7M | $26.7M | $45.0M | $25.5M | $14.5M | $6.6M | $1.6M | $713,937 | $682,433 | $2.0M |
| Operating income | −$29.7M | −$26.7M | −$45.0M | −$25.5M | −$14.5M | −$6.6M | −$1.6M | −$713,937 | −$682,433 | −$1.8M |
| Interest income | $699,061 | $331,849 | $675,921 | $182,712 | $13,335 | $47,225 | — | — | — | — |
| Interest expense | — | $1.9M | — | $182,712 | $13,335 | $47.2M | $40.9M | $66 | $84 | $0 |
| Income before taxes | −$28.9M | −$24.6M | −$56.2M | −$25.3M | −$14.5M | −$5.5M | −$991,000 | −$713,871 | −$682,349 | −$1.7M |
| Income taxes | — | −$24.57B | −$45,035 | −$182,712 | −$50,089 | −$1.2M | −$694,000 | −$132 | −$682,433 | $0 |
| Net income | −$28.9M | −$24.6M | −$56.2M | −$25.1M | −$14.5M | −$5.5M | −$991,000 | −$713,871 | −$682,349 | −$8.3M |
| EBITDA | −$28.9M | −$22.7M | −$56.2M | −$25.5M | −$14.5M | −$5.5M | −$378 | −$713,805 | −$682,433 | — |
| EPS (diluted) | −$1.40 | −$1.94 | −$6.13 | −$3.77 | −$1.90 | −$0.84 | −$0.10 | −$0.10 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | 93.8% |
| Operating margin | — | — | — | — | — | — | — | — | — | −958.1% |
| Net margin | — | — | — | — | — | — | — | — | — | −4,495.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | $13.8M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | −$13.8M |
| Research & development | $12.01B | $16.72B | $8.8M | $6.3M | $5.2M | $5.0M | $5.0M | $2.7M | $5.8M | $6.5M | $8.9M | $13.8M |
| Sales, general & admin | $2.37B | $1.29B | $955,151 | $1.1M | $1.1M | $1.3M | $1.8M | $1.7M | $2.0M | $1.3M | $1.5M | $1.0M |
| Total operating expenses | $14.4M | $18.0M | $9.7M | $7.4M | $6.3M | $6.3M | $6.7M | $4.4M | $7.8M | $7.8M | $10.4M | $14.9M |
| Operating income | −$14.4M | −$18.0M | −$9.7M | −$7.4M | −$6.3M | −$6.3M | −$6.7M | −$4.4M | −$7.8M | −$7.8M | −$10.4M | −$14.7M |
| Interest income | $160,233 | $137,800 | $167,737 | $152,317 | $191,395 | $187,612 | $126,273 | $135,430 | $25,978 | $44,168 | $66,130 | $146,655 |
| Interest expense | $1.6M | — | — | — | — | — | $16,939 | $524,068 | $1.3M | — | $19.7M | — |
| Income before taxes | −$14.8M | −$17.6M | −$9.8M | −$7.3M | −$6.2M | −$5.5M | −$5.9M | −$12.6M | −$5.0M | −$1.1M | −$22.2M | −$14.7M |
| Income taxes | — | — | — | — | — | — | −$5 | −$12.64B | $2 | $3 | −$10,442 | $131,790 |
| Net income | −$14.8M | −$17.6M | −$9.8M | −$7.3M | −$6.2M | −$5.5M | −$5.9M | −$12.6M | −$5.0M | −$1.1M | −$22.2M | −$14.7M |
| EBITDA | −$14.4M | −$17.6M | −$9.8M | −$7.3M | −$6.2M | −$5.5M | −$5.9M | −$12.1M | −$3.7M | −$1.1M | −$22.2M | −$14.7M |
| EPS (diluted) | −$0.40 | −$0.63 | −$0.39 | −$0.37 | −$0.32 | −$0.32 | −$0.43 | −$0.97 | −$0.44 | −$0.10 | −$2.24 | −$1.63 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ANVS's financial statements (latest annual report filed March 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ANVS financial results
Annovis Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $28.9 million. Diluted earnings per share came to −$1.40.
See the ANVS stock overview for the latest quote and news, or the ANVS chart for price history and technical indicators.
ANVS income statement FAQ
Does Annovis Bio have revenue?
Annovis Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Annovis Bio profitable?
No. Annovis Bio reported a net loss of $28.9 million in fiscal 2025.
How much does Annovis Bio spend on research and development?
Annovis Bio spent $25.2 million on research and development in fiscal 2025.
What are Annovis Bio's earnings per share?
Annovis Bio earned $-1.40 per diluted share in fiscal 2025, compared with $-1.94 a year earlier.
When does Annovis Bio's fiscal year end?
Annovis Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 13, 2026.